Market Introduction
High-throughput screening (HTS) is a drug discovery process that allows automated testing of large numbers of chemical and/or biological compounds for a specific biological target. High-throughput screening methods are extensively used in the pharmaceutical industry, leveraging robotics and automation to quickly test the biological or biochemical activity of many molecules, usually drugs. They accelerate target analysis, as large-scale compound libraries can quickly be screened in a cost-effective way. HTS is a useful tool for assessing for instance pharmacological targets, pharmacologically profiling agonists and antagonists for receptors (such as GPCRs) and enzymes.
Market Overview and Dynamics
The Asia Pacific high throughput screening market is expected to reach US$ 6,142.79 million by 2028 from US$ 3,321.07 million in 2021; it is estimated to register a CAGR of 9.2% from 2021 to 2028. Driving factors such as an increase in investment in research and development by the pharmaceutical and biotechnology industry and the introduction of technologically advanced products in the high throughput screening market are driving the growth of the market. However, the lack of proper automation methods is obstructing the growth of the market.
Prime vendors have earmarked a few Asia Pacific countries that have huge potential for the drug discovery market. Research and development expenditure in countries such as China and India is growing, which has led to a rise in demand for high throughput screening (HTS) systems for conducting various genetic, chemical, and pharmacological tests that aid the drug discovery process starting from drug design to trials and interactions. Various countries in APAC are capable of adopting advanced HTS technologies; they are engaged in the development of cost-effective and high-performance systems to become advanced drug developers in the world. Governments of these emerging countries have also spent significantly on encouraging research in the life sciences industry. Moreover, the increasing interest of pharmaceutical companies in drug discovery outsourcing due to the ever-increasing demand for better drugs, limited drug pipelines, and rising R&D costs is further fueling the demand for HTS techniques in emerging markets. China and India have many contract research organizations that offer drug discovery services to serve pharmaceutical and biotechnology companies. Furthermore, the increasing incidence of various diseases in Asia Pacific has escalated the demand for novel drug discovery in the region. Governments are also enforcing regulations to encourage the use of high-throughput screening methods for various pharma and biotech companies. Furthermore, there is an increase in demand for high-throughput screening owing to the need for screening new chemical entities with more efficiency and productive optimization of drug molecules. Technological advancements in high-throughput screening techniques and the launch of innovative systems by various market players are expected to propel the market growth.
Countries in Asia Pacific are facing challenges due to increasing incidences of COVID-19 confirmed cases. However, many countries, such as South Korea, Japan, and Singapore, efficiently contained the situation through robust tracking and testing. This has increased the demand for high-throughput screening in the region. India is increasing its testing capacity to control the rising number of COVID-19 cases. New laboratories are being set up to conduct COVID-19 tests. State governments in the country are adopting various strategies to increase the testing capacity. The recent restrictions imposed by many countries in response to the recent COVID-19 outbreak have impacted ongoing clinical research. As these restrictions are now being lifted, the research activities are gaining momentum. The demand for clinical research is on the rise in Asia Pacific. Thus, the above-mentioned factors are positively impacting the market growth.
Key Market Segments
The Asia Pacific high throughput screening market, based on product and service, is subsegmented into consumables, instruments, accessories, software, and services. The consumables segment is further subsegmented into reagents, assay kits, and laboratory equipment. The instruments are further sub-divided into liquid handling systems and detection systems. In 2021, the consumables segment is expected to hold the largest share of the market and is expected to register the highest CAGR during 2021–2028.
The Asia Pacific high throughput screening market, based on technology, was subsegmented into cell-based assays, lab-on-a-chip, ultra-high-throughput screening, bioinformatics, and label-free technology. In 2021, the cell-based assays segment is expected to hold the largest share of the market; however, the lab-on-a-chip segment is expected to register the highest CAGR during the forecast period.
The Asia Pacific high throughput screening market, based on application, is subsegmented into drug discovery, biochemical screening, life sciences research, and other applications. In 2021, the drug discovery segment is expected to hold the largest share of the market and is expected to register the highest CAGR during the forecast period.
The Asia Pacific high throughput screening market, based on end user, is subsegmented into pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations (CRO), and others. In 2021, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the market; however, the contract research organizations (CRO) segment is expected to register the highest CAGR during the forecast period.
Major Sources and Companies Listed
A few of the primary and secondary sources associated with this report on the Asia Pacific high throughput screening market are the University of Tokyo Edge Capital (UTEC), National Center for Biotechnology Information (NCBI) and Medical Research Future Fund (MRFF).
Reasons to buy the report
ASIA PACIFIC HIGH THROUGHPUT SCREENING MARKET SEGMENTATION
By Product and Services
By Technology
By Application
By End User
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,321.07 Million |
| Market Size by 2028 | US$ 6,142.79 Million |
| CAGR (2021 - 2028) | 9.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product and Service
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific High Throughput Screening Market is valued at US$ 3,321.07 Million in 2021, it is projected to reach US$ 6,142.79 Million by 2028.
As per our report Asia Pacific High Throughput Screening Market, the market size is valued at US$ 3,321.07 Million in 2021, projecting it to reach US$ 6,142.79 Million by 2028. This translates to a CAGR of approximately 9.2% during the forecast period.
The Asia Pacific High Throughput Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific High Throughput Screening Market report:
The Asia Pacific High Throughput Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific High Throughput Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific High Throughput Screening Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific High Throughput Screening Market
